Pharma

projects tracked
177
active
68
countries
27

Chemicals and intermediates used in pharmaceutical manufacturing and drug development.

Projects in pharma

chemXplore tracks 177 projects in pharma, of which 68 are active.

  1. 27 projects Announced / Concept
  2. none FEED / Pre-FID
  3. 1 project FID / Sanctioned
  4. 35 projects Under Construction
  5. 4 projects Commissioning & Start-up
  6. 1 project Qualification & Validation

Of the active ones, 37 expansion, 28 new construction and 3 revamp / retrofit.

Expected start-up, by year
0 5 10 15 2026 2027 2028 2029 2030 2031

24 active projects carry no start-up date yet. The dates themselves, per project, are for subscribers.

What moved recently

  • 12 November 2026 Lilly Lehigh Valley injectable medicine and device plant · Under Construction · United States
  • November 2026 Evonik Tippecanoe Lipid Innovation Center, Lafayette · Commissioning & Start-up · United States
  • 22 October 2026 Lilly Goochland bioconjugate API and drug product plant · Under Construction · United States
  • 14 October 2026 Merck ADVANCE bioanalytical research facility, West Point · Operational / Completed · United States
  • 5 October 2026 Aptar Pharma Taloja Inhalation Technologies Expansion · Operational / Completed · India

Latest news in pharma

17 November 2026
GSK wins US approval for Nelkarmi in previously treated ALK-positive lung cancer

The accelerated approval covers adults with advanced disease after alectinib alone, or after at least two ALK inhibitors and platinum chemotherapy.

16 November 2026
Evonik’s Self Driving Labs platform wins CPHI award

AI and automated equipment design, run and evaluate API process experiments, with reported throughput of up to 100 experiments a day.

16 November 2026
Johnson & Johnson to buy Ollin Biosciences for $2.2bn

The deal would add OLN324, a Phase 3 bispecific antibody candidate for retinal diseases, to its ophthalmology pipeline.

16 November 2026
Novo Nordisk reports semaglutide trial results in children with obesity

In the phase 3 STEP Young trial, BMI fell over 68 weeks with semaglutide alongside diet and activity changes; the treatment remains investigational for children under 12 in the US.

16 November 2026
Novo reports early bone-protection signals from amylin and calcitonin receptor agonists

Findings span an ovariectomized-rat model, small human biomarker studies and exploratory analyses from the 68-week REDEFINE 1 trial.

16 November 2026
Roche wins FDA approval for Wilserdly in ESR1-mutated advanced breast cancer

The oral giredestrant–everolimus regimen cut the risk of progression or death by 62% versus endocrine therapy plus everolimus in phase III testing.

15 November 2026
Novo reports 25.4% mean weight loss among early CagriSema responders

A post hoc analysis of REDEFINE 1 found 67.8% reached at least 5% weight loss by week 8; separate analyses reported improved physical and psychosocial function.

15 November 2026
Genentech’s Gazyva wins first FDA approval for primary membranous nephropathy

The approval covers adults at risk of disease progression and follows Phase III results showing higher remission rates than tacrolimus.

14 November 2026
Novo reports 21% weight loss with lower-dose CagriSema in phase 3 trial

The 68-week REDEFINE 9 study compared two dose levels with placebo in 309 adults with overweight or obesity without diabetes.

13 November 2026
Novo wins EU approval for FREHEMGO in haemophilia A

The subcutaneous treatment offers monthly, every-two-weeks or weekly prophylaxis via a single-use pre-filled pen.

Where its projects are

active all projects

The 8 with the most active projects, of 27 countries.